GLP-1 Receptor Agonists: Mechanisms Explained

You have been eating less and exercising more. You have done the calorie counting, the portion control, the 10,000 steps. And for a while, it works. Then your body fights back. The hunger gets louder, the cravings get harder to ignore, and the weight comes back. This is not a willpower problem. It is your biology doing exactly what it evolved to do: protect your energy stores.

GLP-1 receptor agonists, the class of medications that includes Ozempic, Wegovy, and Mounjaro, work by changing the biological signals that drive this cycle. They target the hormones and brain circuits responsible for hunger, fullness, and metabolic regulation. This article explains how they work, what happens in your body when you take them, and what clinical trials have shown about their effectiveness.

What is GLP-1 and what does it normally do?

GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut produces naturally after you eat, particularly after carbohydrates and fats reach your small intestine.

Natural GLP-1 does several things:

• Tells your pancreas to release insulin (but only when blood sugar is elevated, which is why GLP-1 medications rarely cause low blood sugar on their own)
• Signals your brain that food has arrived and you can stop eating
• Slows down how quickly food leaves your stomach, so you feel full longer
• Reduces glucagon, a hormone that raises blood sugar

The problem is that natural GLP-1 is destroyed within two to three minutes by an enzyme called DPP-4. It barely lasts long enough to do its job.

GLP-1 receptor agonists are synthetic versions of this hormone, engineered to resist DPP-4 breakdown. Semaglutide (the active ingredient in Ozempic and Wegovy) has a half-life of about seven days, which is why it works as a once-weekly injection. This extended duration means it can activate GLP-1 receptors throughout the body far more powerfully than the natural hormone ever does.

How GLP-1 medications affect your brain

The most important effect of GLP-1 receptor agonists happens in the brain. This is what makes them different from older weight loss medications that mainly worked on the gut or metabolism.

Appetite suppression in the hypothalamus

GLP-1 receptors sit on neurons in the hypothalamus, the brain region that controls hunger and energy balance. When semaglutide activates these receptors, two things happen:

1. Appetite-suppressing neurons (POMC/CART) switch on. These neurons release signals that reduce hunger and increase energy expenditure.
2. Hunger-promoting neurons (NPY/AgRP) switch off. These are the neurons responsible for the drive to seek food. GLP-1 medications suppress them through indirect inhibition via GABA signalling.

The net effect: you feel less hungry between meals, you feel satisfied with less food, and the constant mental chatter about food (what patients often call "food noise") quiets down.

Reducing reward-driven eating

GLP-1 medications also act on the brain's reward system, specifically the ventral tegmental area and nucleus accumbens. These are the same circuits involved in addiction. In people with obesity, these circuits can become hyperactive around food, making high-calorie foods feel disproportionately rewarding.

Semaglutide reduces dopamine release in these reward centres, which lowers the pull of hedonic eating, the kind of eating driven by pleasure rather than hunger. This is why many patients report that they can walk past their favourite bakery without the usual struggle, or keep chocolate in the house without thinking about it constantly.

Research also shows that GLP-1 medications improve leptin sensitivity. Leptin is a hormone produced by fat cells that should tell your brain you have enough energy stored. In obesity, the brain often becomes resistant to leptin's signal. By restoring sensitivity, GLP-1 medications help your brain accurately read your body's energy status.

How GLP-1 medications affect your digestive system

Beyond the brain, GLP-1 receptor agonists have direct effects on the gut.

Delayed gastric emptying

GLP-1 medications slow down how fast food moves from your stomach into your small intestine. They do this by relaxing the upper stomach (the fundus) while tightening the lower stomach (the antrum and pylorus). The result is that food sits in your stomach longer, which activates stretch receptors that send fullness signals to your brain through the vagus nerve.

This is why many patients report feeling satisfied after half a meal, or finding that a portion that used to feel normal now feels like too much.

This effect is strongest with short-acting GLP-1 medications like exenatide (Byetta), but injectable semaglutide still produces meaningful delayed gastric emptying even as the body partially adapts over time.

Reduced gastric acid secretion

GLP-1 also reduces how much acid your stomach produces, which contributes to the feeling of fullness and may explain why some patients experience less heartburn on treatment.

The gastric emptying effect is also why doctors advise eating smaller meals and chewing thoroughly while on GLP-1 medications. Large meals can sit in a slowed stomach and cause nausea, bloating, or reflux.

Metabolic and hormonal effects

GLP-1 receptor agonists do more than just reduce appetite. They have direct metabolic effects that improve how your body handles blood sugar, fat, and cholesterol.

Blood sugar regulation

GLP-1 medications enhance insulin secretion from pancreatic beta cells, but only when blood sugar is elevated. This glucose-dependent mechanism means they carry a much lower risk of hypoglycaemia compared to older diabetes drugs like sulfonylureas. They also suppress glucagon from alpha cells, reducing glucose production by the liver.

In clinical trials, semaglutide reduced HbA1c (a measure of average blood sugar over three months) by 1.0% to 1.8%, depending on the population and dose.

Fat reduction and lipid improvements

GLP-1 receptor agonists reduce both visceral fat (the metabolically dangerous fat around organs) and subcutaneous fat. They also reduce fat accumulation in the liver, which is relevant for patients with non-alcoholic fatty liver disease.

Lipid improvements include:

• Triglycerides reduced by approximately 12-15% (semaglutide trials)
• LDL cholesterol modestly reduced
• Small improvements in HDL cholesterol

Cardiovascular protection

The SELECT trial (2023) followed 17,604 overweight or obese adults with existing cardiovascular disease for over three years. Semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% compared to placebo. This was the first trial to demonstrate cardiovascular benefit specifically in overweight and obese patients without diabetes.

Earlier trials had shown cardiovascular benefits for GLP-1 use in type 2 diabetes: the LEADER trial found liraglutide 1.8 mg reduced major cardiovascular events by 13% (HR 0.87) in patients with type 2 diabetes over 3.8 years.

Tirzepatide: the dual agonist

Tirzepatide (Mounjaro) works differently from semaglutide because it activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

GIP is another gut hormone that affects insulin sensitivity and fat tissue signalling. By combining GLP-1 and GIP receptor activation, tirzepatide produces stronger weight loss than GLP-1 agonists alone.

In the SURMOUNT-1 trial, tirzepatide at the 15 mg dose achieved 20.9% mean weight loss (ITT analysis) over 72 weeks, compared to 14.9% for semaglutide 2.4 mg in STEP 1 over 68 weeks. At the highest dose, 39.7% of participants lost 25% or more of their body weight.

Tirzepatide also produced notable metabolic improvements: triglycerides reduced by 20-25%, systolic blood pressure reduced by 6-8 mmHg (placebo-adjusted), and significant improvements in insulin sensitivity.

What clinical trials show about weight loss

The evidence for GLP-1 receptor agonists comes from large, randomised controlled trials involving thousands of participants.

Semaglutide (Wegovy) trial results

In STEP 1, 86.4% of participants lost at least 5% of their body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. For context, the placebo group lost 2.4%.

The STEP 5 trial is particularly relevant because it ran for two full years, showing that weight loss was maintained at 104 weeks with continued treatment.

Tirzepatide (Mounjaro) trial results

Liraglutide (Saxenda) trial results

Saxenda, the older daily-injection GLP-1, produces more modest results: approximately 8% weight loss in non-diabetic patients over 56 weeks (SCALE Obesity trial). While less effective than semaglutide or tirzepatide, it remains an option for patients who prefer a different dosing schedule or have specific clinical reasons.

Oral semaglutide

The current oral formulation (Rybelsus 14 mg) was developed for type 2 diabetes and produces modest weight loss of 3-5%. Newer high-dose oral formulations (25-50 mg) are approaching injectable efficacy: the OASIS 1 trial showed 15.1% weight loss at 68 weeks with the 50 mg dose.

Common side effects and how they relate to the mechanism

Most side effects of GLP-1 medications are a direct consequence of how they work:

Nausea and vomiting occur because of delayed gastric emptying. Food sits in the stomach longer, which can feel uncomfortable, especially after large or fatty meals. These symptoms are most common during the first four to eight weeks and during dose increases. The titration schedule (starting at a low dose and increasing gradually) is designed to minimise this.

Constipation or diarrhoea result from GLP-1's effects on gut motility throughout the digestive tract.

Reduced appetite is the intended effect, but some patients find it unsettling when their relationship with food changes significantly. This is worth discussing with your doctor.

Rare but serious risks include pancreatitis (GLP-1 may increase risk in susceptible individuals), gallbladder disease (rapid weight loss increases gallstone risk), and a theoretical thyroid concern. GLP-1 medications caused thyroid C-cell tumours in rodent studies, but this has not been confirmed in humans. Doctors will not prescribe GLP-1 medications to anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

What GLP-1 medications do not do

It is worth being clear about what these medications cannot do:

• They do not replace exercise. Weight lost on GLP-1 includes some lean mass (muscle), and resistance training is the primary way to protect against this.
• They do not work without any dietary changes. While appetite suppression makes eating less feel natural, patients still need to prioritise protein intake (1.0-1.2 g per kg body weight daily) and nutrient-dense foods.
• They do not produce permanent results if stopped. The STEP 4 trial showed that patients who stopped semaglutide after 20 weeks regained about two-thirds of the weight they had lost by week 68. The biological drivers of weight regain (increased hunger, reduced metabolic rate) return when the medication stops.
• They are not appropriate for everyone. BMI criteria, medical history, and current medications all determine eligibility. See our guide on what doctors check before prescribing GLP-1.

Pipeline medications: what is coming next

The field is moving quickly. Several next-generation medications are in late-stage trials:

Retatrutide (Eli Lilly) is a triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 data from the TRIUMPH-4 trial showed 28.7% weight loss at 68 weeks with the 12 mg dose. Seven additional Phase 3 trials are expected to complete in 2026.

CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, a long-acting amylin analogue. The REDEFINE 1 trial showed 20.4% weight loss at 68 weeks. Novo Nordisk filed for FDA approval in December 2025.

Survodutide (Boehringer Ingelheim) is a dual GLP-1/glucagon agonist. Phase 2 data showed up to 18.7% weight loss at 46 weeks. Phase 3 results are expected in the first half of 2026.

These medications suggest that the next generation of weight loss treatments may produce even greater results, though they will still require medical supervision and lifestyle changes.

GLP-1 medications in Singapore

In Singapore, GLP-1 medications are available by prescription. The BMI thresholds for eligibility are lower than international standards because Asian populations develop metabolic complications at lower body weights:

• BMI 27.5 or above: eligible without other conditions
• BMI 24 or above with a weight-related condition (type 2 diabetes, hypertension, high cholesterol, PCOS, sleep apnoea)

Trimly is an MOH-licensed telehealth clinic that provides GLP-1 treatment through video consultations. Treatment plans range from $350 to $650 per month and include the consultation, medication, home delivery, and unlimited follow-ups.

For more on treatment options, see our comparison of oral vs injectable GLP-1 or our guide to long-term GLP-1 treatment.

Key takeaways

GLP-1 receptor agonists work through multiple mechanisms: suppressing appetite in the brain, slowing gastric emptying, improving blood sugar regulation, and reducing cardiovascular risk. Clinical trials consistently show 15-21% weight loss depending on the medication and dose. They are most effective when combined with dietary changes and exercise, and they require ongoing medical supervision. If you are considering GLP-1 treatment, the first step is a consultation with a doctor who can assess whether these medications are appropriate for your situation.